These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 18325838)
21. Peroxisome proliferator-activated receptor gamma agonists in the prevention and treatment of murine systemic lupus erythematosus. Aprahamian TR; Bonegio RG; Weitzner Z; Gharakhanian R; Rifkin IR Immunology; 2014 Jul; 142(3):363-73. PubMed ID: 24456224 [TBL] [Abstract][Full Text] [Related]
22. EGR2 is elevated and positively regulates inflammatory IFNγ production in lupus CD4 Dai R; Heid B; Xu X; Xie H; Reilly CM; Ahmed SA BMC Immunol; 2020 Jul; 21(1):41. PubMed ID: 32646370 [TBL] [Abstract][Full Text] [Related]
23. Apolipoprotein E-knockout mice on high-fat diet show autoimmune injury on kidney and aorta. Wang Y; Lu H; Huang Z; Lin H; Lei Z; Chen X; Tang M; Gao F; Dong M; Li R; Lin L Biochem Biophys Res Commun; 2014 Jul; 450(1):788-93. PubMed ID: 24953693 [TBL] [Abstract][Full Text] [Related]
24. Administration of activated lymphocyte-derived DNA accelerates and aggravates lupus nephritis in B6/lpr mice: a new approach to modify a lupus murine model. Zhu Y; Yue Y; Xiong S Clin Exp Immunol; 2018 Sep; 193(3):302-312. PubMed ID: 29704464 [TBL] [Abstract][Full Text] [Related]
25. Fas and Fas ligand mutations inhibit autoantibody production in pristane-induced lupus. Satoh M; Weintraub JP; Yoshida H; Shaheen VM; Richards HB; Shaw M; Reeves WH J Immunol; 2000 Jul; 165(2):1036-43. PubMed ID: 10878381 [TBL] [Abstract][Full Text] [Related]
26. Vascular Inflammation and Dysfunction in Lupus-Prone Mice-IL-6 as Mediator of Disease Initiation. Marczynski P; Meineck M; Xia N; Li H; Kraus D; Roth W; Möckel T; Boedecker S; Schwarting A; Weinmann-Menke J Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669022 [TBL] [Abstract][Full Text] [Related]
27. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis. Chalmers SA; Glynn E; Garcia SJ; Panzenbeck M; Pelletier J; Dimock J; Seccareccia E; Bosanac T; Khalil S; Harcken C; Webb D; Nabozny G; Fine JS; Souza D; Klein E; Herlitz L; Ramanujam M; Putterman C Clin Immunol; 2018 Dec; 197():205-218. PubMed ID: 30339790 [TBL] [Abstract][Full Text] [Related]
28. Cd72(c) is a modifier gene that regulates Fas(lpr)-induced autoimmune disease. Xu M; Hou R; Sato-Hayashizaki A; Man R; Zhu C; Wakabayashi C; Hirose S; Adachi T; Tsubata T J Immunol; 2013 Jun; 190(11):5436-45. PubMed ID: 23616572 [TBL] [Abstract][Full Text] [Related]
31. Regulation of T cell-dependent autoantibody production by a gammadelta T cell line derived from lupus-prone mice. Fujii T; Okada M; Craft J Cell Immunol; 2002; 217(1-2):23-35. PubMed ID: 12425998 [TBL] [Abstract][Full Text] [Related]
32. Up-regulation of transcription factor Blimp1 in systemic lupus erythematosus. Luo J; Niu X; Liu H; Zhang M; Chen M; Deng S Mol Immunol; 2013 Dec; 56(4):574-82. PubMed ID: 23911415 [TBL] [Abstract][Full Text] [Related]
33. A bacterial artificial chromosome transgene with polymorphic Cd72 inhibits the development of glomerulonephritis and vasculitis in MRL-Faslpr lupus mice. Oishi H; Tsubaki T; Miyazaki T; Ono M; Nose M; Takahashi S J Immunol; 2013 Mar; 190(5):2129-37. PubMed ID: 23365086 [TBL] [Abstract][Full Text] [Related]
34. Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis. Woo JM; Lin Z; Navab M; Van Dyck C; Trejo-Lopez Y; Woo KM; Li H; Castellani LW; Wang X; Iikuni N; Rullo OJ; Wu H; La Cava A; Fogelman AM; Lusis AJ; Tsao BP Arthritis Res Ther; 2010; 12(3):R93. PubMed ID: 20482780 [TBL] [Abstract][Full Text] [Related]
35. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice. Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682 [TBL] [Abstract][Full Text] [Related]
36. Anti-oxLDL antibody isotype levels, as potential markers for progressive atherosclerosis in APOE and APOECD40L mice. Smook ML; van Leeuwen M; Heeringa P; Damoiseaux JG; Theunissen R; Daemen MJ; Lutgens E; Tervaert JW Clin Exp Immunol; 2008 Nov; 154(2):264-9. PubMed ID: 18778362 [TBL] [Abstract][Full Text] [Related]
37. MRL-lpr/lpr mice exhibit a defect in maintaining developmental arrest and follicular exclusion of anti-double-stranded DNA B cells. Mandik-Nayak L; Seo SJ; Sokol C; Potts KM; Bui A; Erikson J J Exp Med; 1999 Jun; 189(11):1799-814. PubMed ID: 10359584 [TBL] [Abstract][Full Text] [Related]
38. Decreased CD1d level is associated with CD86 over-expression in B cells from systemic lupus erythematosus. Liu F; Ji J; Li X; Li X; Xu J; Yue H; Zhao S; Fan H; Hou Y Acta Biochim Biophys Sin (Shanghai); 2017 Apr; 49(4):328-337. PubMed ID: 28338767 [TBL] [Abstract][Full Text] [Related]
39. The effect of mycophenolate mofetil on disease development in the gld.apoE (-/-) mouse model of accelerated atherosclerosis and systemic lupus erythematosus. Richez C; Richards RJ; Duffau P; Weitzner Z; Andry CD; Rifkin IR; Aprahamian T PLoS One; 2013; 8(4):e61042. PubMed ID: 23577189 [TBL] [Abstract][Full Text] [Related]